Gout
Nearly 25% of patients with chronic kidney disease meet gout criteria
Approximately 23% of patients with chronic kidney disease meet the criteria for gout, of whom 13% have uncontrolled gout and 36% have no formal gout diagnosis, according to data published in Gout, Urate, and Crystal Deposition Disease.
Thermal imaging could aid diagnosis in cellulitis, pseudocellulitis
The use of thermal imaging and the ALT-70 prediction model were helpful in differentiating cellulitis from pseudocellulitis, reducing misdiagnosis, according to a study.
Serum urate predicts 10-year risk for recurrent gout hospitalization, flares
Patients with higher baseline serum urate levels demonstrate increased recurrent gout hospitalization rates and subsequent risk for flare over 10 years of follow-up, according to data published in JAMA.
Cardiovascular disease risk in gout highest for women, young people
Excess risk for cardiovascular disease in patients with gout — including heart failure and arrhythmias — is highest among women and those aged younger than 45 years, according to data published in The Lancet Rheumatology.
Drug choice, dosing strategy impact gout flare risk when starting urate lowering therapy
The risk for gout flare when initiating urate lowering therapy varies based on the drug and dosing strategy used, according to a systematic review and network meta-analysis published in Arthritis Care & Research.
Weather changes fail to impact risks for osteoarthritis pain, rheumatoid arthritis
Weather changes are not risk factors for rheumatoid arthritis or knee, hip or low back pain, but do appear to influence gout flares, according to a meta-analysis published in Seminars in Arthritis and Rheumatism.
Gout flare severity, recurrence risk not impacted by timing of urate lowering therapy
Starting urate lowering therapy during a gout flare does not impact the flare’s severity, duration or risk for recurrence over the following month, according to a systematic review and meta-analysis.
Biologics fill ‘very unique niches’ in gout management
SCOTTSDALE, Ariz. — Although many rheumatologists may not reach for biologic therapies for gout management, interleukin-1 and 6 inhibitors may have utility in managing mobilization flares, according to a speaker here.
Multiple mechanisms, multiple benefits: SGLT2 inhibition shows promise in lupus, gout
Last November, at the American College of Rheumatology Convergence 2023, several faculty members presented new data on how a class of drugs used in type 2 diabetes may also be beneficial in patients with lupus and gout.
FDA approves Uloric generic for chronic hyperuricemia management in gout
The FDA has approved an abbreviated new drug application for Lupin Limited’s generic febuxostat 40 mg and 80 mg tablets, according to a press release from the manufacturer.